In AF or VTE, acenocoumarol or phenprocoumon dosing by genotype did not affect time in therapeutic range

被引：0
|
作者：
Dunn, Andrew [1 ]
机构：
[1] Mt Sinai Hlth Syst, New York, NY 10029 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2014年 / 160卷 / 06期
关键词：
D O I：
10.7326/0003-4819-160-6-201403180-02010
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 39 条
  • [21] CYP3A5 Genotype is Associated with Lower Tacrolimus Time in Therapeutic Range After Heart Transplantation
    Robinson, Katherine
    Horn, Edward
    Wood-Trageser, Michelle
    Randhawa, Parmjeet
    Venkataramanan, Raman
    Empey, Philip
    PHARMACOGENETICS AND GENOMICS, 2025, 35 (01): : 41 - 42
  • [22] RANDOMIZED COMPARISON OF TWO APPROACHES TO INITIAL WARFARIN DOSING: TIME IN THERAPEUTIC RANGE OF INTERNATIONAL NORMALIZED RATIO DURING HOSPITALIZATION
    Mishchenko, L. N.
    Averkov, O., V
    Gordeev, I. G.
    Levchuk, N. N.
    Vechorko, V., I
    KARDIOLOGIYA, 2017, 57 (09) : 42 - 46
  • [23] Relationship between center time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial
    Piccini, J. P.
    Harrell, F.
    Lokhnygina, Y.
    Wang, J.
    Oppenheimer, L.
    Patel, M. R.
    Singer, D. E.
    Mahaffey, K. W.
    Fox, K. A. A.
    Califf, R. M.
    EUROPEAN HEART JOURNAL, 2012, 33 : 968 - 969
  • [24] Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)
    Madhavan, Malini
    Holmes, DaJuanicia N.
    Piccini, Jonathan P.
    Freeman, James, V
    Fonarow, Gregg C.
    Hylek, Elaine M.
    Kowey, Peter R.
    Mahaffey, Kenneth W.
    Pieper, Karen
    Peterson, Eric D.
    Chan, Paul S.
    Allen, Larry A.
    Singer, Daniel E.
    Naccarelli, Gerald, V
    Reiffel, James A.
    Steinberg, Benjamin A.
    Gersh, Bernard J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 132 : 66 - 71
  • [25] Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
    Pokorney, Sean D.
    Simon, DaJuanicia N.
    Thomas, Laine
    Fonarow, Gregg C.
    Kowey, Peter R.
    Chang, Paul
    Singer, Daniel E.
    Ansell, Jack
    Blanco, Rosalia G.
    Gersh, Bernard
    Mahaffey, Kenneth W.
    Hylek, Elaine M.
    Go, Alan S.
    Piccini, Jonathan P.
    Peterson, Eric D.
    AMERICAN HEART JOURNAL, 2015, 170 (01) : 141 - U194
  • [26] Racial Disparities in Warfarin Time in INR Therapeutic Range in Patients With Atrial Fibrillation: Findings From the TREAT-AF Study
    Yong, Celina
    Xu, Xiangyan
    Than, Claire
    Ullal, Aditya
    Schmitt, Susan
    Azarbal, Farnaz
    Heidenreich, Paul
    Turakhia, Mintu
    CIRCULATION, 2013, 128 (22)
  • [27] Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
    Singer, Daniel E.
    Hellkamp, Anne S.
    Piccini, Jonathan P.
    Mahaffey, Kenneth W.
    Lokhnygina, Yuliya
    Pan, Guohua
    Halperin, Jonathan L.
    Becker, Richard C.
    Breithardt, Guenter
    Hankey, Graeme J.
    Hacke, Werner
    Nessel, Christopher C.
    Patel, Manesh R.
    Califf, Robert M.
    Fox, Keith A. A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2013, 2 (01):
  • [28] Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge
    Wasniewski, Samantha
    Consuegra-Sanchez, Luciano
    Conesa-Zamora, Pablo
    Garcia de Guadiana-Romualdo, Luis
    Ramos-Ruiz, Pablo
    Merelo-Nicolas, Marta
    Guillermo Clavel-Ruiperez, F.
    Alburquerque-Gonzalez, Begona
    Soria-Arcos, Federico
    Castillo-Moreno, Juan A.
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [29] Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study
    Kim, Y. -K.
    Nieuwlaat, R.
    Connolly, S. J.
    Schulman, S.
    Meijer, K.
    Raju, N.
    Kaatz, S.
    Eikelboom, J. W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) : 101 - 106
  • [30] Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic hepatitis C virus genotype 1
    Kinugasa, Hideaki
    Ikeda, Fusao
    Okada, Hiroyuki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 382 - 382
1234